Results 61 to 70 of about 5,762,549 (184)

Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy

Medicine Bulletin, Volume 2, Issue 1, Page 61-93, January 2026.
ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley   +1 more source

Treatment Choices for Tenosynovial Giant Cell Tumor: Surgery or Observation?

Zhongliu Fangzhi Yanjiu
Tenosynovial giant cell tumor (TGCT) is a rare mesenchymal tumor that clinically presents as nodular-type or diffuse-type (D-TGCT). D-TGCT is more aggressive, has a higher surgical recurrence rate, and can potentially lead to severe joint destruction ...
Hairong XU, Jing CHEN, Xiaohui NIU
doaj   +1 more source

1821P Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT) [PDF]

Annals of Oncology, 2021
H. Gelderblom, A.R. Abdul Razak, A. Sánchez-Gastaldo, P. Rutkowski, B. Wilky, A. Wagner, M. van de Sande, M. Michenzie, M. Vallee, M. Sharma, M.L. Sherman, R. Ruiz-Soto, W. Tap   +12 more
openaire   +1 more source

Prognostic Significance and Immune Correlation of CCL3 Expression in Colon Adenocarcinoma: Insights From Multidatabase Analysis

Biochemistry Research International, Volume 2026, Issue 1, 2026.
Objective Colon adenocarcinoma (COAD) remains a leading cause of cancer‐related mortality, necessitating reliable prognostic biomarkers. This study explored the potential prognostic role of C‐C motif chemokine ligand 3 (CCL3) and its association with immune‐related signatures in COAD.
Vikrant Kumar, Nawaid Hussain Khan, Shashi Nandar Kumar, Neeraj Mahajan, Wafa Aziz, Vinay Kumar, Chaitenya Verma, Harleen Khatra   +7 more
wiley   +1 more source

Chondroid Tenosynovial Giant Cell Tumor of the Temporomandibular Joint: A Rare Case Report [PDF]

, 2017
Tenosynovial giant cell tumor of diffuse type (TGCT-d) or pigmented villonodular synovitis (PVNS) is a locally aggressive lesion that mostly affects the joints of long bones.
Oslei Paes de Almeida, Barbara Maria Corrêa Geraldo, Geraldo, Barbara Maria Corrêa [UNESP], Ana Lia Anbinder, Carvalho, Yasmin Rodarte, Guimarães Filho, Rubens, Anbinder, Ana Lia [UNESP], Carvalho, Yasmin Rodarte [UNESP], Almeida, Oslei Paes de, Débora Lima Pereira, Anbinder, Ana Lia, Rubens Guimarães Filho, Yasmin Rodarte Carvalho, Geraldo, Barbara Maria Corrêa, de Almeida, Oslei Paes, Pereira, Débora Lima   +15 more
core   +1 more source

Unusual Presentation and Surgical Treatment of a Phosphaturic Mesenchymal Tumor in a Knee

Frontiers in Surgery, 2022
A 30-year-old woman presented to our hospital with an 11-year history of gradually enlarging masses around the left knee and 2-year history of progressively worsening bone pain.
Juan Sun, Xi Zhou, Weibo Xia, Huanwen Wu, Shuzhong Liu, Huizhen Wang, Yong Liu   +6 more
doaj   +1 more source

Tenosynovial giant cell tumor of the suboccipital region - A rare, benign neoplasm in this location

, 2020
Tenosynovial giant cell tumors (TGCTs) are benign neoplasms that arise from the synovium of tendon sheaths, bursae, and joints.
Ganjoo, Kristen, Kolahi, Kevin S, Cayrol, Romain, Stienen, Martin N, Born, Donald E, Singh, Rahul, Zygourakis, Corinna C, Charville, Gregory W   +7 more
core   +1 more source

Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial

Acta Orthopaedica, 2021
Background and purpose — The ENLIVEN trial showed that, after 25 weeks, pexidartinib statistically significantly reduced tumor size more than placebo in patients with symptomatic, advanced tenosynovial giant cell tumor (TGCT) for whom surgery was not ...
Michiel Van De Sande, William D Tap, Heather L Gelhorn, Xin Ye, Rebecca M Speck, Emanuela Palmerini, Silvia Stacchiotti, Jayesh Desai, Andrew J Wagner, Thierry Alcindor, Kristen Ganjoo, Javier Martín-Broto, Qiang Wang, Dale Shuster, Hans Gelderblom, John H Healey   +15 more
doaj   +1 more source

Tenosynovial Giant Cell Tumor Treatment Revolution: Vimseltinib's Edge Over Pexidartinib

Medicine Advances, Volume 3, Issue 4, Page 372-373, December 2025.
This paper compares vimseltinib and pexidartinib in treating TGCT, highlighting key differences in their efficacy and safety, with vimseltinib showing better tumor reduction. Vimseltinib is more selective for CSF1R, leading to fewer side effects and no liver toxicity, whereas pexidartinib carries a higher risk of hepatotoxicity.
Muhammad Affan Abid, Syed Azfar Hussain, Muhammad Ali Kamal   +2 more
wiley   +1 more source

Medical Management of Tenosynovial Giant Cell Tumor

Diffuse tenosynovial giant cell tumor (D-TGCT) is a benign neoplasm with locally aggressive potential of the synovium, bursae, and tendon sheaths. This review summarizes the current treatment landscape for D-TGCT, with a focus on systemic therapies ...
Palmerini, Emanuela, Trent, Jonathan C, Hornicek, Jr, Francis John   +2 more
core   +1 more source